共抑制受体在银屑病中的研究进展  

Research Progress of Co-inhibitory Receptors in Psoriasis

作　　者：刘宇超 白彦萍[2] 王磊[2] LIU Yuchao;BAI Yanping;WANG Lei

机构地区：[1]北京中医药大学,北京100029 [2]中日友好医院皮肤病与性病科,北京100029

出　　处：《新中医》2022年第3期16-20,共5页New Chinese Medicine

基　　金：国家自然科学基金项目(81904210)。

摘　　要：目前银屑病的发病机制尚不明确,随着对于机制研究的不断深入,生物制剂作为治疗的新手段以其独有的优势正逐步应用于临床,其中针对共抑制受体的靶向药物在治疗多种疾病中取得显著疗效。中医治疗银屑病具有显著优势,其作用于人体具有多途径多靶点的特征。本文就共抑制受体在银屑病相关方面的研究进展进行综述,以期对银屑病中共抑制受体的靶向治疗提供依据,同时为中医药治疗银屑病的研究和应用提供新思路。At present, the pathogenesis of psoriasis is not clear. With the deepening of mechanism research, biological agents, as a new method of treatment, are gradually applied to clinic with their unique advantages. Among them, targeted drugs targeting co-inhibitory receptors have achieved remarkable curative effects in the treatment of a variety of diseases.Traditional Chinese medicine has significant advantages in the treatment of psoriasis. Its effect on the human body has the characteristics of multi-channel and multi-target. This paper reviews the research progress of co-inhibitory receptors in psoriasis, in order to provide basis for the targeted treatment of co-inhibitory receptors in psoriasis, and provide new ideas for the research and application of traditional Chinese medicine in the treatment of psoriasis.

关 键 词：银屑病 共抑制受体 中医药 综述 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]